Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 “Repibresib” approved as the non-proprietary name for VYN201 by USAN BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced completion of enrollment in the Phase 2b trial evaluating VYN201 gel for the treatment of nonsegmental vitiligo. Top-line data from the 24-week vehicle-controlled treatment period are expected in…